Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

The selection of ALK-TKI based on the rebiopsy result was associated with a high ORR and relatively short PFS. The mechanism responsible for the short PFS of sensitive ALK-TKI to secondary mutation should be clarified.